| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M |
| P698 | PubMed publication ID | 9304767 |
| P2093 | author name string | Daniels MJ | |
| Hughes MD | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 1965-1982 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Statistics in Medicine | Q7604438 |
| P1476 | title | Meta-analysis for the evaluation of potential surrogate markers. | |
| P478 | volume | 16 |
| Q38803203 | A Bayesian hierarchical surrogate outcome model for multiple sclerosis |
| Q35016789 | A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables |
| Q38691539 | A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses |
| Q39836056 | A multipoint method for meta-analysis of genetic association studies |
| Q37967642 | A statistician's perspective on biomarkers in drug development. |
| Q37553617 | A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials |
| Q36740970 | A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials |
| Q37064401 | Accounting for treatment by center interaction in sample size determinations and the use of surrogate outcomes in the pessary for the prevention of preterm birth trial: a simulation study |
| Q51875233 | Alternative methods to evaluate trial level surrogacy. |
| Q43117880 | An alternative pseudolikelihood method for multivariate random-effects meta-analysis |
| Q52907578 | An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker. |
| Q34718431 | An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. |
| Q47750413 | An improved method for bivariate meta-analysis when within-study correlations are unknown. |
| Q38763752 | An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest |
| Q30540217 | Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge |
| Q64055679 | Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy |
| Q58784082 | Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer |
| Q51476184 | Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials. |
| Q92990218 | Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data |
| Q37106499 | Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process |
| Q36381197 | Bayesian methods for evidence synthesis in cost-effectiveness analysis |
| Q51263625 | Bayesian multivariate meta-analysis with multiple outcomes. |
| Q37810197 | Biomarkers and Imaging: Physics and Chemistry for Noninvasive Analyses |
| Q35912696 | Biomarkers and surrogate endpoints in glaucoma clinical trials |
| Q36831404 | Biomarkers of treatment response in clinical trials of novel antituberculosis agents |
| Q92310472 | Bivariate network meta-analysis for surrogate endpoint evaluation |
| Q33269179 | Bivariate random-effects meta-analysis and the estimation of between-study correlation |
| Q35044261 | Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials |
| Q35167912 | Clinical biomarkers in drug discovery and development |
| Q55221052 | Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl. |
| Q28740935 | Comparing biomarkers as principal surrogate endpoints |
| Q39869593 | Comparing biomarkers as trial level general surrogates |
| Q37101600 | Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective |
| Q34386133 | Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop |
| Q35886464 | Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges |
| Q36224801 | Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa |
| Q39467318 | Design and estimation for evaluating principal surrogate markers in vaccine trials |
| Q33805412 | Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis |
| Q33870594 | Effective incorporation of biomarkers into phase II trials |
| Q35979625 | Epistasis Test in Meta-Analysis: A Multi-Parameter Markov Chain Monte Carlo Model for Consistency of Evidence |
| Q47894497 | Estimating causal treatment effects from longitudinal HIV natural history studies using marginal structural models |
| Q36745021 | Estimating within-study covariances in multivariate meta-analysis with multiple outcomes. |
| Q88492832 | Estimation of the optimal surrogate based on a randomized trial |
| Q37107029 | Evaluating a surrogate endpoint at three levels, with application to vaccine development |
| Q53399534 | Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework. |
| Q38707640 | Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling |
| Q38233353 | Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review |
| Q78726678 | Evaluating surrogate endpoints |
| Q35672166 | Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes |
| Q34103118 | Evidence-based medicine as Bayesian decision-making |
| Q33194319 | Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics |
| Q40268629 | Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints |
| Q47430316 | Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials |
| Q46450711 | Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis |
| Q42026879 | Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project |
| Q36767997 | Inference for correlated effect sizes using multiple univariate meta-analyses |
| Q37016467 | Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints |
| Q35640178 | Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies. |
| Q27025943 | Is blood pressure reduction a valid surrogate endpoint for stroke prevention? [etc.] |
| Q41638355 | Likelihood-based methods for evaluating principal surrogacy in augmented vaccine trials |
| Q41215381 | Links between analysis of surrogate endpoints and endogeneity |
| Q37964985 | MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials |
| Q40121515 | Measuring the public-health impact of candidate HIV vaccines as part of the licensing process |
| Q37553613 | Mediation and moderation of treatment effects in randomised controlled trials of complex interventions |
| Q43787549 | Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling |
| Q37458317 | Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. |
| Q40268622 | Meta-analysis in Stata using gllamm |
| Q37405745 | Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease |
| Q40028428 | Multiparameter evidence synthesis in epidemiology and medical decision-making |
| Q33587615 | Multivariate meta-analysis of mixed outcomes: a Bayesian approach |
| Q30976009 | Multivariate meta-analysis using individual participant data. |
| Q33804037 | Multivariate meta-analysis: potential and promise |
| Q97527451 | Multivariate network meta-analysis incorporating class effects |
| Q37362990 | On assessing surrogacy in a single trial setting using a semicompeting risks paradigm |
| Q39657029 | On the covariance of two correlated log-odds ratios |
| Q45029688 | On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints |
| Q57286668 | Optimizing and evaluating biomarker combinations as trial-level general surrogates |
| Q45288765 | Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer |
| Q35556037 | Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time |
| Q82320343 | Principal stratification and attribution prohibition: good ideas taken too far |
| Q33800697 | Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer |
| Q41845098 | Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach |
| Q47784321 | Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. |
| Q46286212 | Related causal frameworks for surrogate outcomes |
| Q36811255 | Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection |
| Q48288136 | Should we rely on trials with disease- rather than patient-oriented endpoints? |
| Q98612742 | Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening |
| Q35035407 | Statistical challenges in the evaluation of surrogate endpoints in randomized trials |
| Q38356102 | Statistical evaluation of surrogate endpoints with examples from cancer clinical trials |
| Q44081925 | Substantial evidence of effect |
| Q44019265 | Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy |
| Q35792872 | Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy |
| Q36727471 | Surrogate endpoint analysis: an exercise in extrapolation |
| Q77597779 | Surrogate endpoints: the debate goes on |
| Q38829245 | Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques |
| Q30758427 | Surrogate markers and joint models for longitudinal and survival data |
| Q35862680 | Surrogate markers for time-varying treatments and outcomes |
| Q57380290 | Synthesis of evidence on heterogeneous interventions with multiple outcomes recorded over multiple follow-up times reported inconsistently: a smoking cessation case-study |
| Q38523764 | Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies |
| Q34307827 | Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis |
| Q36966415 | The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat |
| Q43544469 | The evaluation of multiple surrogate endpoints |
| Q36327987 | The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. |
| Q34570123 | The promise and peril of surrogate end points in cancer research |
| Q59901332 | The search for surrogate endpoints for immunotherapy trials |
| Q41484464 | Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints |
| Q64110618 | Using a surrogate marker for early testing of a treatment effect |
| Q45192037 | Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach |
Search more.